NYSE:ABBV AbbVie Q3 2026 Earnings Report $259.14 -0.79 (-0.30%) As of 10:51 AM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast AbbVie EPS ResultsActual EPSN/AConsensus EPS $3.86Beat/MissN/AOne Year Ago EPSN/AAbbVie Revenue ResultsActual RevenueN/AExpected Revenue$17.31 billionBeat/MissN/AYoY Revenue GrowthN/AAbbVie Announcement DetailsQuarterQ3 2026Date10/30/2026TimeBefore Market OpensConference Call DateFriday, October 30, 2026Conference Call Time9:00AM ETConference Call ResourcesEarnings HistoryCompany Profile AbbVie Earnings HeadlinesRINVOQ Drives Continued Skin Repigmentation Through Week 76 In AbbVie StudiesOctober 1 at 10:38 PM | rttnews.comAbbVie (ABBV) Stock May Be 41% Undervalued Following JUVMO ApprovalOctober 1 at 5:37 PM | finance.yahoo.comElon Warns "America Will Go Bankrupt". Trump's Plan Inside.National debt just crossed 40 trillion dollars, and Elon Musk says America is 1,000% going to go bankrupt without major changes. As former head of the Department of Government Efficiency under President Trump, Musk saw firsthand how looming spending cuts could rattle markets and squeeze 401ks, IRAs, and TSPs. A preserved IRS provision may help everyday investors shield their retirement savings before the next wave of volatility hits.October 2 at 1:00 AM | American Hartford Gold (Ad)ABBV Stock Rises 25% in 6 Months: Time to Buy, Hold or Sell?October 1 at 12:36 PM | finance.yahoo.comAbbVie to Host Third-Quarter 2026 Earnings Conference CallOctober 1 at 12:36 PM | finance.yahoo.comAbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on ItOctober 1 at 12:36 PM | finance.yahoo.comSee More AbbVie Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like AbbVie? Sign up for Earnings360's daily newsletter to receive timely earnings updates on AbbVie and other key companies, straight to your email. Email Address About AbbVieAbbVie (NYSE:ABBV) is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health. The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care. AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories. Based in North Chicago, Illinois, the company serves patients and healthcare professionals in the United States and international markets. Robert A. Michael has served as AbbVie’s chief executive officer since July 2024.View AbbVie ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Micron’s Earnings Reveal Why the AI Memory Boom May Last LongerAnthropic's IPO Could Put Amazon's and Alphabet's Paper Profits to the TestBoeing’s Fighter Victory Opens the Door to Decades of Defense RevenueCleared for Takeoff: AAR Corp. Expands Its Aerospace Aftermarket ReachJabil’s Double-Beat and Raise Is a Signal That This Rally Will ContinueMicrosoft's AI Spending Didn't Change—Wall Street's View of It DidL3Harris’ $6 Billion THAAD Win Comes at a Crucial Moment for the Stock Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
